News
ALIM
3.900
0.00%
0.000
Alimera Sciences Price Target Announced at $10.00/Share by Maxim Group
Dow Jones · 3d ago
Alimera Sciences Initiated at Buy by Maxim Group
Dow Jones · 3d ago
Maxim Group Initiates Coverage On Alimera Sciences with Buy Rating, Announces Price Target of $10
Benzinga · 3d ago
Weekly Report: what happened at ALIM last week (0318-0322)?
Weekly Report · 3d ago
The top stocks with buying pressure across the Russell universe - Jefferies
The top stocks with buying pressure across the Russell universe. Jefferies analysts highlighted names in the FTSE Russell indices with the biggest buying pressures on the passive side. These are the top 10 buys for passive investors by dollars and the top ten buys by days to trade, based on trading volume over the last 10 days.
Seeking Alpha · 03/20 15:40
Weekly Report: what happened at ALIM last week (0311-0315)?
Weekly Report · 03/18 11:33
New Strong Sell Stocks for March 13th
NASDAQ · 03/13 11:56
Weekly Report: what happened at ALIM last week (0304-0308)?
Weekly Report · 03/11 11:29
Alimera Sciences Price Target Raised to $6.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 03/08 18:12
Alimera Sciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/08 18:12
HC Wainwright & Co. Maintains Buy on Alimera Sciences, Raises Price Target to $6
Benzinga · 03/08 18:01
Buy Rating Affirmed for Alimera Sciences Amid Strong Financial Performance and Promising Clinical Trials
Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a $6.00 price target. Alimera Sciences’ strong financial performance and favorable growth prospects are cited as factors. The ongoing clinical trial for ILUVIEN in Diabetic Macular Edema presents a potential catalyst for the stock.
TipRanks · 03/08 17:25
ALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023
Alimera Sciences reported earnings per share of -7 cents. The company reported revenue of $26.31 million. This was 8.08% better than the analyst estimate of $24.34 million for the company's quarterly report. The stock was down 0.7%.
Investorplace · 03/07 17:52
Alimera Sciences Inc reports results for the quarter ended in December - Earnings Summary
Alimera Sciences Inc reports results for the quarter ended in December. Revenue rose 87.5% to $26.31 million from a year ago. The company reported a quarterly loss of $3.78 million. Alimera sciences Inc shares had fallen by 10.4% this quarter.
Reuters · 03/07 16:03
Analysts Are Bullish on Top Healthcare Stocks: Alimera (ALIM), Avid Bioservices (CDMO)
Two analysts have maintained Buy ratings on Alimera and Avid Bioservices. Craig-Hallum analyst Alexander Nowak maintained a Buy rating on the Healthcare sector stock today. The company’s shares closed at $3.87 on Tuesday. The analyst consensus is a Strong Buy for both companies.
TipRanks · 03/07 13:40
Alimera Sciences GAAP EPS of -$0.07, revenue of $26.31M beats by $1.97M
Seeking Alpha · 03/07 12:38
*Alimera Sciences Now Sees 2024 Revenue Topping $105M >ALIM
Dow Jones · 03/07 12:33
*Alimera Sciences Sees 2024 Adjusted Ebitda Margin Topping 20% >ALIM
Dow Jones · 03/07 12:33
Alimera Sciences Q4 EPS $(0.07) Up From $(0.54) YoY, Sales $26.31M Beat $24.34M Estimate
Alimera Sciences reported quarterly sales of $26.31 million. The company beat the analyst consensus estimate of $24.34 million by 8.08%. The company reported quarterly losses of $0.07 per share. This is a 87.04 percent increase over the same period last year.
Benzinga · 03/07 12:32
Press Release: Alimera Sciences Reports Fourth -2-
A live conference call will be hosted today, at 9:00 a.m. EST, to discuss Alimera's financial results and provide an update on corporate developments. The conference call and webcast will be available through a live webcast. The call is scheduled to be held on March 7, 2024. A replay of the call will also be available on the company's website.
Dow Jones · 03/07 12:30
More
Webull provides a variety of real-time ALIM stock news. You can receive the latest news about Alimera Sciences through multiple platforms. This information may help you make smarter investment decisions.
About ALIM
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.